---
schema_version: "secwatch.filing_event.v1"
accession: "0001599901-24-000071"
form_type: "8-K"
ticker: null
cik: "0001599901"
company_name: "Avidity Biosciences, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:03:37.982390+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avidity Q1 cash $915.9M, Phase 3 HARBOR trial on track, positive long-term DM1 data

## Summary
- Cash position $915.9M at Q1 end after $400M private placement; funding into late 2026.
- Phase 3 HARBOR trial for del-desiran in DM1 to initiate Q2 2024; FDA Breakthrough Therapy designation.
- Long-term MARINA-OLE data showed reversal of DM1 progression on vHOT, muscle strength, daily activities.
- R&D expenses $66.8M (up 40% YoY); collaboration revenue $3.5M (up 59% YoY).
- Upcoming: FSHD FORTITUDE preliminary data Q2 2024, DMD EXPLORE44 5 mg/kg data 2H 2024.

## SEC filing metadata
- accession: 0001599901-24-000071
- form_type: 8-K
- cik: 0001599901
- company_name: Avidity Biosciences, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/0001599901-24-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/rna-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599901-24-000071
- JSON: https://secwatch.observer/filing/0001599901-24-000071.json
- Plain text: https://secwatch.observer/filing/0001599901-24-000071.txt

## Key facts
- Earnings Releases
  Avidity Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Avidity Biosciences, Inc. issued a press release announcing its financial results for the quarter and year ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/0001599901-24-000071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.